Close
Almac
Achema middle east

ASM Research Chemicals Launches Development Packs for API Manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...
- Advertisement -

ASM Research Chemicals, a contract research and development services provider specialized in organic chemistry, is launching its new development pack (DevPack) service intended for active pharmaceutical ingredients (APIs) manufacturing.

The service was developed and optimized across ten core partners to establish a standardized and robust dataset of development process steps. Now fully optimized and streamlined, the DevPack service is commercially available to help overcome resource bottlenecks and streamline API research, development, troubleshooting and scale-up activities.

“The concept of DevPacks has evolved since 2019 and we can now prepare them within six to twelve months, depending on the complexity of the synthesis,” said James Lawler, head of ASM Research Chemicals. Datasets cover route scouting and optimization with a focus on commercial viability and the cleanest chemistry possible, identification of critical process parameters (CPP’s) through design of experiment (DoE) methodology, and initial identification of critical safety parameters for all steps. The DevPack is beneficial for contract manufacturing organizations (CMOs) or pharmaceutical companies seeking to speed-up the early-stage development of manufacturing routes for synthetic or extracted APIs.”

The DevPack also covers analytical method development for IPC and release methods, setting of proposed specifications, fate / purge studies and genotoxic assessments for process impurities to facilitate regulatory submissions. In parallel, preparation of non-GMP samples up to 100 grams is available to help ease the transition into subsequent GMP scale-up operations.

“Reliable CMC data allows the customer to focus on the scale-up and GMP validation operations at commercial manufacturing facilities without having to tie up resources for non-GMP organic chemistry and analytical work in the lab,” said Lawler. “Our skilled team of PhD Chemists understand the depth, sensitivity, and confidentiality of these projects. Now that we have completed an extensive evaluation, we will further streamline and standardize this service for the market.”

Additional non-GMP scale-up services have been expanded with a kilo-lab setup for stress testing the scalability of the designed chemistry. According to the company, when needed, impurities can be manufactured to accelerate analytical method validation and complete purge studies.

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »